China's Feihe issues profit warning
In a stock-exchange filing, the Hong Kong listed company said revenue could be down as much as 10% in the six months to 30 June, while net profit could be down as much as 47% from the same period a year earlier.
Feihe put forward a revenue range of 9.1bn yuan ($1.2bn) to 9.3bn yuan for the period, compared to the reported figure of 10.1bn yuan in the corresponding six months.
Net profit, meanwhile, was flagged at 1bn yuan to 1.2bn yuan, down from the actual 1.9bn yuan a year earlier.
Feihe attributed the expected declines to several factors, including 'childbirth subsidies' to consumers, a decrease in government grants, and an 'impairment provision' for whole milk powder products.
It also cited inventory adjustments to ensure product freshness as a contributing factor to the anticipated declines.
However, the company projects a 'low single-digit increase' in revenue for the full year 2025 compared to the prior year, with inventory adjustments expected to be completed by the third quarter.
It plans to release its half-yearly results by the end of August.
The company also announced a share buyback plan, allocating at least 1bn yuan from existing cash reserves to repurchase shares for 'subsequent sales' or employee incentives.
The board said total dividends for FY 2025 will be 'no less than' 2bn yuan, despite the anticipated 'short-term" financial challenges.
Feihe's primary products include infant milk formula, adult milk powder, liquid milk, and goat milk infant formula.
Its formula brands include Astrobaby and Organic Zhenzhi.
Feihe issued a similar first-half profit warning back in August 2023 ahead of its final annual results.
It later reported that full-year net profit increased 11.1% to 3.6bn yuan in the 12 months to 31 December 2024. Revenue climbed 6.2% to 20.7bn yuan.
In contrast, it posted a profit of 3.2bn yuan in fiscal 2023, down 33.5%, while revenue dropped 8.3% year-on-year to 19.5bn yuan.
"China's Feihe issues profit warning" was originally created and published by Just Food, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
ROCKVILLE, Md. and SUZHOU, China, July 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ('Ascentage Pharma' or the 'Company'), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced the appointments of Veet Misra, Ph.D., as the Company's Chief Financial Officer, and Mr. Eric Huang, as Senior Vice President of Global Corporate Development and Finance. Both Dr. Misra and Mr. Huang will report directly to Dajun Yang, M.D., Ph.D., the Company's Chairman & Chief Executive Officer. Dr. Yang said, 'I am excited to welcome Veet and Eric to our senior management team. As an innovative biopharmaceutical company dual listed on the Hong Kong Stock Exchange and Nasdaq, Ascentage Pharma is entering a phase of notable growth. The addition of these seasoned executives will help accelerate the implementation of our global strategy of becoming a leading, fully integrated global biopharmaceutical company.' Dr. Misra brings a rare combination of deep scientific background in biology and significant experience in U.S. capital markets in the biopharmaceutical sector. 'I am confident that Veet's unique blend of scientific acumen and capital markets expertise can help us garner stronger traction in the global capital markets and strengthen our operations,' added Dr. Yang. Mr. Huang brings rich expertise in the global pharmaceutical industry and a wealth of experience in corporate management. 'This makes Eric a great match for Ascentage Pharma's long-term growth needs. His experience will help drive excellence in Ascentage Pharma's corporate operations as the Company continues to make headway in expanding globally,' said Dr. Yang. Dr. Misra commented, 'I am thrilled to join Ascentage Pharma as its Chief Financial Officer. Ascentage Pharma is a global leader in apoptosis-targeted therapies. Its dual listing in Hong Kong and the U.S. reflects strong recognition of the Company in these two premier markets. I look forward to working with my colleagues to accelerate the global development of the Company's innovative pipeline and create sustained value for patients and shareholders.' Mr. Huang said, 'It is my great honor to join Ascentage Pharma, a company that has established growing global competitiveness in the field of hematologic malignancies. The strategic partnership with Takeda and the dual listing in Hong Kong and the U.S. have created a sound foundation for global expansion. I look forward to working closely with the Company's management team to further improve operations and efficiently integrate the Company's existing resources to accelerate the global development and commercialization of its core assets, ultimately bringing more novel therapeutics to patients in need.' Dr. Misra has more than 20 years of experience in investment banking. Prior to joining Ascentage Pharma, he was a Managing Director in the Healthcare Investment Banking group at Cantor Fitzgerald where he covered the biopharmaceutical sector. Before that, he worked in the life sciences investment banking groups at Houlihan Lokey and RBC Capital Markets. Over the course of his banking career, Dr. Misra advised on deals spanning equity, equity-linked, debt, and debt restructuring, as well as buy-side/sell-side M&A and corporate strategy, primarily focusing on the biotechnology sector. Dr. Misra earned a Ph.D. in Molecular Biology, with a focus on the oncology field, from the University of Toronto and an MBA in Finance & Strategy from the Schulich School of Business in Toronto. Mr. Huang has served in various managerial positions at multinational companies for more than 20 years and possesses extensive experience in driving continuous financial performance improvement, business/operational excellence, and global operations. Prior to joining Ascentage Pharma, Mr. Huang served as the Chief Financial Officer for Greater China and Asia-Pacific at Beigene, where he also led Global Technical Operations Finance and Global Commercial Finance, and implemented comprehensive financial planning management and optimized globally-based resource allocation leading to sustained financial improvements. Before that, Mr. Huang was at Novartis, where he served as the head of finance for multiple countries and regions. Mr. Huang received an MBA in Finance from Dowling Business School. About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting 4 global registrational Phase III trials: the GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the GLORA-4 study in patients with newly diagnosed higher risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ContactsInvestor Relations:Hogan Wan, Head of IR and StrategyAscentage 512 85557777 Stephanie CarringtonICR (646) 277-1282 Media Relations:Sean LeousICR (646) 866-4012
Yahoo
34 minutes ago
- Yahoo
Nvidia stock: Why investors are bullish again
Nvidia (NVDA) stock has rebounded from April lows as investor concerns around tariffs, China, and artificial intelligence (AI) capital expenditure (CapEx) risks have eased. Patrick Moorhead, founder, CEO, and chief analyst at Moor Insights & Strategy, joins Market Domination Overtime to explain why optimism around industrial and enterprise AI is keeping demand and spending alive. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Let's begin with Nvidia. Big run off the April low. A name a lot of people know. A name a lot of people watching right now, certainly own. What explains that move off the April low? Yeah, so a lot of risks were taken down, you know, it was screaming for so long and then tariffs hit, uh, China hit, uh, potential GDP concerns, even questions about capex. And nearly all of them just completely evaporated and came off the table. So the risk is lower in the perception with investors. And for the first time, this year, this year of the potential next wave of Industrial AI, investors are starting to see the correlation, the potential upside. You mentioned capex, which is an interesting point because there were some skeptics we had on the show who were arguing perhaps that maybe 2025 is going to represent some sort of high mark, some sort of peak in AI capex, and that was bad news for the likes of Nvidia. Do you buy that? Uh, I don't, but I do think the growth will be tempered, right? Well, we see 10% growth, 20% growth likely. We won't be seeing 50% growth. But the other, the only thing that could change my mind on that is I'm doing a little bit more research on the industrial edge and also enterprise AI because as AI gets permeated into everything, into businesses, on premises, and even in the industrial edge, somebody is going to have to pay for that equipment. And if it's not going to be who you might expect, let's say the carriers, uh, the folks who are out there investing in it today, other companies might have to come in, let's say the hyperscalers go after that.
Yahoo
38 minutes ago
- Yahoo
South Korea to step up US trade talks before tariffs kick in on August 1
By Jack Kim SEOUL (Reuters) -South Korea said it planned to intensify trade talks with the United States and considers U.S. President Donald Trump's plan for a 25% tariff from August 1 as effectively extending a grace period on implementing reciprocal tariffs. Trump said on Monday he would impose the tariff on goods from South Korea starting on August 1, posting a letter to President Lee Jae Myung on his social media platform along with one to Japan's leader. South Korea's Industry Ministry said in a statement that the letter effectively extends a grace period on the implementation of reciprocal tariffs by the United States. "We will step up negotiations during the remaining period to reach a mutually beneficial result to quickly resolve the uncertainties from tariffs," it said. "We also plan to use it as an opportunity to improve domestic systems and regulations to resolve the trade deficit that is a major interest of the United States and advance key industries through a manufacturing renaissance partnership between the two countries," it said. South Korea's top trade envoy and presidential security adviser have traveled to the United States in recent days for trade and defence talks as Asia's fourth largest economy races to seek an exemption from Trump's threatened tariffs. The Industry Ministry in the statement conceded it did not have enough time after the start of a new administration in South Korea to reach an agreement with the United States on all issues despite intense negotiations. South Korean President Lee took office on June 4 after winning a snap election after his predecessor's December martial law declaration, which he said had greatly impaired the country's response to U.S. trade policy and new tariffs.
